Both spleen and bone marrow-derived CD4 and CD8 T cells showed a significant increase in tumor-specific IFN-γ producing cells when mice were treated with anti-PD-L1 in combination with anti-TIM-3, or anti-LAG-3 or anti-CTLA4 as compared to anti-PD-L1 alone (Figure 4A). This evidence concerns the gene CD4 and neoplasm.